来源：市场资讯 （来源：京城夜读） 今日走势：今日还是按照之前判断的那样，震荡走势，跌不慌，涨不追，这一阶段还是围绕这种节奏操作，控制仓位，缩量行情下，避免风险排 首位。 指数方面，上证指数慢牛不变，指数低开但韧性十足，还处于震荡筑底阶段，短期无主升行情，围绕箱体震荡。中证500，1000前期涨幅大，调 整幅度也会大，以控制风险为主，而上证50位置偏低，这几天也确实好一些。 短线方面，今日情绪不高，前期风口有色大跌对情绪面压制较大，资金流向老登如白酒，金融，而科技等普遍调整，这时候要注意，不要追涨杀 跌，两头挨打。 方向上看，今日消费，地产，金融活跃领涨，科技，光伏，半导体等调整为主。 预判次日：指数处于缩量震荡阶段，操作上偏保守，尽量避免高位风险，低吸高抛。方向上，关注商业航天，光伏，算力，电力。 风口解读+风口核心股分析 猜想：指数主升期后调整阶段，题材见顶退潮引发情绪冰点，老主线退潮后新主线萌芽试盘阶段。 1）有色：启动：1月9日，今日：延续分歧！ 逻辑：黄金白银价格再创历史新高+各类能源金属陆续上涨 结论：今日金银大跌，有色板块再次缩量杀跌，后续看金银企稳止跌后，板块会同步止跌，酝酿超跌反弹行情，后续 ...

李霁阳 方正证券医药分析师: 各位投资人下午好，我是方正证券医药组的分析师李季阳，然后我们今天的周周谈的会议 的话，是总结一下，据拼某个会议当中，中国创效公司的一些更新和进展。然后另外的话 就是大家对于近期整个整体创效的这个调整。然后我们也做一个市场的一个解读。首先的 话， JP Morgan 是在上周末结束，然后像百济百天恒，科伦博泰这些公司也是在主会场做 了这个 presentation 那我们可以看到其实公司的这个进展还是非常多的。就首先百济的 话，它的这个 BCL 2 是在中国已经获批上市了，而且年内的话，是有望在这个美国获得一 个加速的获批。 那 BCL2 其实对于百济来说，也相当于是它的第二个驱动增长的一个引擎，因为 BTK BK 我们可以看到近两年在美国市场的这个销售增速是非常快的。那我们预计的话，BCL2 上 市之后也会补全在一线 C CL 这个适应症当中的。这个拼图，然后也会助力它在未来两年 继续保持这个高速增长。因为其实投资人还是对于未来几年这个 BDK 的一个增速，因为 它毕竟体量提量到了一个比较大的一个这个体量了。就后续的增速其实大家还是有一些质 疑和担心，但是 BCL 2 上市之后， ...

Group 1 - The company, Xinxing Co., Ltd. (688257.SH), primarily engages in the production of hard alloys and tools [1] - The company has not yet ventured into the brain-machine interface sector [1]

Core Viewpoint - The arrival of Optimus V3 is anticipated to be a transformative technological product, potentially overshadowing Tesla's automotive legacy, as suggested by prominent figures in Silicon Valley [2]. Group 1 - Elon Musk's recent comment "probably true" regarding the Optimus V3 indicates a level of confidence in the product's development [2]. - Jason, a Silicon Valley angel investor and friend of Musk, claims to have seen Optimus V3 and believes it will produce 1 billion units, marking a significant shift in technological history [2]. - Musk has been actively promoting concepts related to commercial space travel, brain-machine interfaces, and embodied robotics, with the news of Optimus V3's performance exceeding expectations serving as a potential foundation for its engineering implementation [5].

Group 1 - The core viewpoint of the news highlights a strong recovery in the innovative drug sector, with significant stock price increases and positive market sentiment returning to the pharmaceutical industry [1][2] - The Hong Kong pharmaceutical ETF (159718.SZ) has risen by 2.77%, marking a seven-day consecutive increase, driven by strong performances from constituent stocks such as Rongchang Biologics, which rose by 10.56%, and WuXi AppTec, which increased by 7.40% [1] - Rongchang Biologics has entered a substantial licensing agreement with AbbVie for a core dual-antibody product, with an upfront payment of $650 million and potential milestone payments totaling up to $4.95 billion, exceeding expectations [1] Group 2 - WuXi AppTec has announced a revenue forecast for 2025 of 45.456 billion yuan, representing a year-on-year growth of 15.84%, and an adjusted net profit of 14.957 billion yuan, reflecting a 41.33% increase, indicating accelerated performance [1] - Recent market trends show a recovery in the pharmaceutical sector, with emerging hotspots in brain-computer interfaces, small nucleic acid drugs, and AI healthcare, suggesting promising investment opportunities in the industry [1][2] - The innovative drug sector is expected to remain the most important investment theme in the pharmaceutical industry through 2026, with improving market conditions and catalysts expected to drive stock prices [2]

Group 1 - The market shows resilience, achieving a 15-day consecutive rise despite initial declines, indicating potential for further growth [1] - The current market sentiment is driven by the commercial aerospace sector, with key emotional anchors being航发 and胜通, which significantly influence market dynamics [1] - The performance of航发 and胜通 will be critical in shaping market sentiment in the coming days, necessitating close monitoring [1] Group 2 - The commercial aerospace sector saw 24 stocks hitting the daily limit up, reflecting a strategy of high sell-low buy and low-position recovery [2] - Other sectors such as brain-machine interfaces, intelligent driving, robotics, and nuclear power are experiencing rotation, benefiting from the overall positive market sentiment [2] - The potential for a return to previously performing themes exists as long as the market remains favorable, providing opportunities for bottom-fishing investors [2]

个人观点仅供参考，文章中任何内容均不对您构成任何投资建议，据此操作，风险自担。 股市有风险，投资需谨慎。 压单又来了，就在今天收盘时，中信出现了14.5亿的压单，很多人担心，这是不是意味着行情要调整 了？其实不然，前面有两次类似的情况发生，分别是9月17日和10月24日，对应的压单有30亿和10亿， 30亿那次确实调整了一下，但是没两天就涨回来了，而10月24日之后是直接高举高打，所以这个压单顶 多就是心理层面的一些影响，又或者是上峰想要慢牛的一种体现，短期看来或许市场有调整的需求，但 是14连阳创历史的走法，意味着短期如果有调整，也会吸引更多资金涌入进来，因此调整大概率会成为 踏空者上车的好机会。 说回到题材上，真是铁打的商业航天，流水的其他题材，今天商业航天再次出现13家涨停，而且咱们说 的两个特征得到体现，一个是高位核心辨识度的高抛低吸，另一个是低位补涨挖掘，接下来还是这样， 直到这个方向出现亏钱效应再说。其次就是芯片和机器人，这个昨晚我们刚讲过，人形机器人和国产芯 片倒仍有一战之力，今天这两块都有表现，芯片更是涨停14家，比商业航天还强，不过别忘了前面说 的，铁打的商业航天，流水的其他题材，既然前有脑 ...

Core Viewpoint - The article expresses skepticism towards brain-machine interfaces, particularly the idea of invasive procedures like cranial implants, highlighting psychological barriers associated with such technologies [1] Group 1 - The author identifies as a technology enthusiast but has strong reservations about brain-machine interfaces due to the invasive nature of cranial implants [1] - A poll is suggested to gauge public willingness to accept such implants if mass-produced by companies like Elon Musk's [1]

Core Viewpoint - The computer and software development industry is showing strong growth potential supported by government policies, with significant advancements in key areas such as AI, quantum technology, and integrated circuits as outlined in the 14th and 15th Five-Year Plans [1] Industry Summary - The computer industry is projected to grow by 17% by 2025, with a price-to-earnings (PE) ratio reaching 292 and a price-to-sales (PS) ratio maintaining around 4, indicating high market attention on cutting-edge technologies [1] - The industry's fundamentals are stabilizing, with a year-on-year revenue increase of 10% and a net profit growth of 37% in the first three quarters of 2025, although cash flow has decreased by 58% due to seasonal collection characteristics [1] - Active themes such as AI applications, quantum technology, commercial aerospace, and low-altitude economy are driving market dynamics, with companies like BaiRong Cloud, TongHuaShun, and DingJie Smart achieving success in the AI sector, while GuoDun Quantum and XingTu Measurement Control are forming product matrices in quantum and aerospace fields [1] - The quality of operations in the industry is improving, with stable R&D investments and good control over sales expenses, suggesting a continuation of high attention and valuation advantages in the future [1] ETF Summary - The software ETF (515230) tracks the software index (H30202), which primarily covers publicly listed companies engaged in software development, sales, and related services, typically characterized by high R&D investments and technological leadership [1]

Group 1 - A new trillion-dollar market opportunity has emerged in the brain-machine interface sector, drawing attention from fans and investors alike [1] - Elon Musk has announced plans for mass production in this field, indicating a significant shift in focus from commercial space ventures to brain-machine technology [1] - The article highlights a growing interest in AI and the US stock market, suggesting a potential overlap with developments in brain-machine interfaces [1]